A Phase 1 interventional study of vorinostat in Tumors, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 18 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During Cycle 1, participants receive a single oral dose of vorinostat 100 mg on Day 1 in a fasted state, Day 3 in a fed state, and Day 19 in a fed state. On Days 5-18, participants receive vorinostat 100 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
Drug: vorinostat
During Cycle 1, participants receive a single oral dose of vorinostat 200 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive vorinostat 200 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
Drug: vorinostat
During Cycle 1, participants receive a single oral dose of vorinostat 400 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 400 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
Drug: vorinostat
During Cycle 1, participants receive a single oral dose of vorinostat 500 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 500 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy on the Cycle 2 and subsequent cycles.(Each cycle will be 26 days.)
Drug: vorinostat
vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
Also known as: MK-0683, L-001079038, suberoylanilide hydroxamic acid (SAHA)
Number of Participants Who Experienced One or More Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 4 years
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 4 years
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
A DLT was defined as an event considered to be related to study treatment and included: 1) Grade 4 neutropenia refractory to treatments persisting more than 5 days; 2) Grade 3 or more severe neutropenic fever; 3) Grade 3 thrombocytopenia requiring blood transfusions or Grade 4 thrombocytopenia; 4) Grade 4 hemoglobin decrease; 5) Grade 3 or more severe non-hematological toxicities other than anorexia, nausea/vomiting, and fatigue. (For the diarrhea, it was defined as not to use the frequency for the grading. For the alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]), it was defined as the case of over 300 IU/L; 6) Grade 3 or more severe anorexia, nausea/vomiting, and fatigue refractory to treatments; and 7) compliance of the study drug, while administrating 14 consecutive days, was less than 50% due to the drug-related adverse experience.
Time frame: Up to 26 days
Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: Day 1: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Cmax of Vorinostat After a Single Oral Dose in a Fed State
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: Day 3: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Tmax of Vorinostat After a Single Oral Dose in a Fed State
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
t½ of Vorinostat After a Single Oral Dose in a Fed State
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
| Milestone | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Started | 3 | 6 | 3 | 6 |
| Completed | 2 | 1 | 3 | 3 |
| Not completed | 1 | 5 | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 | 2 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events | 4 | 6 | 3 | 6 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an Adverse Event | 0 | 1 | 0 | 1 |
A DLT was defined as an event considered to be related to study treatment and included: 1) Grade 4 neutropenia refractory to treatments persisting more than 5 days; 2) Grade 3 or more severe neutropenic fever; 3) Grade 3 thrombocytopenia requiring blood transfusions or Grade 4 thrombocytopenia; 4) Grade 4 hemoglobin decrease; 5) Grade 3 or more severe non-hematological toxicities other than anorexia, nausea/vomiting, and fatigue. (For the diarrhea, it was defined as not to use the frequency for the grading. For the alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]), it was defined as the case of over 300 IU/L; 6) Grade 3 or more severe anorexia, nausea/vomiting, and fatigue refractory to treatments; and 7) compliance of the study drug, while administrating 14 consecutive days, was less than 50% due to the drug-related adverse experience.
| Participants | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1 | 0 | 3 | 0 | 2 |
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
| μM·hours | Vorinostat 100 mg FASTED | Vorinostat 200 mg FASTED | Vorinostat 400 mg FASTED | Vorinostat 500 mg FASTED |
|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State | 1.20 ± 0.27 | 2.31 ± 0.96 | 3.96 ± 1.62 | 3.47 ± 2.21 |
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
| μM·hours | Vorinostat 100 mg FED | Vorinostat 200 mg FED | Vorinostat 400 mg FED | Vorinostat 500 mg FED |
|---|---|---|---|---|
| AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State | 0.98 ± 0.07 | 2.22 ± 0.89 | 4.30 ± 0.37 | 5.93 ± 1.78 |
AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.
| μM·hours | Vorinostat 100 mg Twice-daily | Vorinostat 200 mg Twice-daily | Vorinostat 400 mg Once-daily | Vorinostat 500 mg Once-daily |
|---|---|---|---|---|
| AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration | 1.33 ± 0.23 | 2.76 ± 0.85 | 5.41 ± 2.18 | 6.33 ± 1.53 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| μM | Vorinostat 100 mg FASTED | Vorinostat 200 mg FASTED | Vorinostat 400 mg FASTED | Vorinostat 500 mg FASTED |
|---|---|---|---|---|
| Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State | 0.49 ± 0.15 | 0.77 ± 0.13 | 1.19 ± 0.20 | 1.06 ± 0.52 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| μM | Vorinostat 100 mg FED | Vorinostat 200 mg FED | Vorinostat 400 mg FED | Vorinostat 500 mg FED |
|---|---|---|---|---|
| Cmax of Vorinostat After a Single Oral Dose in a Fed State | 0.21 ± 0.14 | 0.59 ± 0.22 | 0.93 ± 0.12 | 1.35 ± 0.39 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.
| μM | Vorinostat 100 mg Twice-daily | Vorinostat 200 mg Twice-daily | Vorinostat 400 mg Once-daily | Vorinostat 500 mg Once-daily |
|---|---|---|---|---|
| Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration | 0.29 ± 0.25 | 0.84 ± 0.56 | 0.86 ± 0.61 | 1.09 ± 0.30 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
| Hours | Vorinostat 100 mg FASTED | Vorinostat 200 mg FASTED | Vorinostat 400 mg FASTED | Vorinostat 500 mg FASTED |
|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State | 0.84 ± 0.30 | 1.59 ± 0.74 | 2.49 ± 0.86 | 1.91 ± 0.91 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
| Hours | Vorinostat 100 mg FED | Vorinostat 200 mg FED | Vorinostat 400 mg FED | Vorinostat 500 mg FED |
|---|---|---|---|---|
| Tmax of Vorinostat After a Single Oral Dose in a Fed State | 5.66 ± 3.79 | 3.00 ± 0.89 | 3.53 ± 2.33 | 3.17 ± 1.17 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.
| Hours | Vorinostat 100 mg Twice-daily | Vorinostat 200 mg Twice-daily | Vorinostat 400 mg Once-daily | Vorinostat 500 mg Once-daily |
|---|---|---|---|---|
| Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration | 4.66 ± 1.16 | 3.30 ± 1.10 | 4.34 ± 1.53 | 4.61 ± 1.95 |
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
| Hours | Vorinostat 100 mg FASTED | Vorinostat 200 mg FASTED | Vorinostat 400 mg FASTED | Vorinostat 500 mg FASTED |
|---|---|---|---|---|
| Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State | 1.08 ± 0.30 | 1.83 ± 0.53 | 1.90 ± 0.72 | 1.93 ± 0.67 |
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
| Hours | Vorinostat 100 mg FED | Vorinostat 200 mg FED | Vorinostat 400 mg FED | Vorinostat 500 mg FED |
|---|---|---|---|---|
| t½ of Vorinostat After a Single Oral Dose in a Fed State | 1.62 ± 0.45 | 1.36 ± 0.28 | 2.01 ± 1.47 | 1.60 ± 0.66 |
t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.
| Hours | Vorinostat 100 mg Twice-daily | Vorinostat 200 mg Twice-daily | Vorinostat 400 mg Once-daily | Vorinostat 500 mg Once-daily |
|---|---|---|---|---|
| t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration | 1.95 ± 0.54 | 1.42 ± 0.50 | 1.98 ± 1.56 | 1.30 ± 0.41 |
Collected over Up to approximately 4 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat 100 mg | 0/3 (0%) | 0/4 (0%) | 4/4 (100%) |
| Vorinostat 200 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Vorinostat 400 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Vorinostat 500 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Pericardial effusionCardiac disorders | 0/4 | 0/6 | 1/3 | 0/6 |
| Hepatic function abnormalHepatobiliary disorders | 0/4 | 0/6 | 1/3 | 0/6 |
| Renal impairmentRenal and urinary disorders | 0/4 | 0/6 | 1/3 | 0/6 |
| PneumoniaInfections and infestations | 0/4 | 1/6 | 0/3 | 0/6 |
| Event | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg |
|---|---|---|---|---|
| Platelet count decreasedInvestigations | 1/4 | 6/6 | 3/3 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 5/6 | 1/3 | 5/6 |
| NauseaGastrointestinal disorders | 1/4 | 5/6 | 2/3 | 4/6 |
| FatigueGeneral disorders | 2/4 | 5/6 | 2/3 | 5/6 |
| Neutrophil count decreasedInvestigations | 2/4 | 5/6 | 0/3 | 1/6 |
| White blood cell count decreasedInvestigations | 1/4 | 5/6 | 0/3 | 1/6 |
| AnorexiaMetabolism and nutrition disorders | 1/4 | 3/6 | 2/3 | 5/6 |
| VomitingGastrointestinal disorders | 1/4 | 3/6 | 2/3 | 1/6 |
| Blood glucose increasedInvestigations | 1/4 | 2/6 | 1/3 | 4/6 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 1/6 | 1/3 | 3/6 |
| Age, Continuous(Years) | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 59.7 ± 6.7 | 60.5 ± 6.3 | 49.3 ± 21.5 | 57.7 ± 8.3 | 57.6 ± 10.4 |
| Sex: Female, Male(Participants) | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 0 | 0 | 3 |
| Male | 3 | 3 | 3 | 6 | 15 |
| Race (NIH/OMB)(Participants) | Vorinostat 100 mg | Vorinostat 200 mg | Vorinostat 400 mg | Vorinostat 500 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 6 | 3 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2005 to primary completion in Aug 2009, 50 months.
Results were first posted in May 2022, 12 years 8 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 50 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat